Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
Sandra Neumann(University of Bristol), Emily J. Henderson(University of Bristol), Diana Steeds(University of Bristol), Yoav Ben‐Shlomo(University of Bristol), Daisy Gaunt(University of Bristol), William Hollingworth(At Bristol), Jodi Taylor(University of Bristol), Chris Metcalfe(University of Bristol), Alison Bamford(University of Bristol), Stevan R. Emmett(University of Bristol), Alan Whone(Frenchay Hospital)
Cited by 22
Related Papers
A Randomized Trial of Vertebroplasty for Osteoporotic Spinal Fractures
|New England Journal of Medicine|2009|1.4k
World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions
|The Lancet Global Health|2019|1.2k
The epidemiology of Parkinson's disease
|The Lancet|2024|809
Model Transparency and Validation
|Medical Decision Making|2012|803